Clinical Trial

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-10; most recent amendment 2026-04-29.
Trial Details
NCT Number NCT07178912
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Amgen, Ascentage Pharma Group Inc.
Conditions Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Enrollment 60 participants
Start Date 2026-08-27
Primary Completion 2031-09-30 (estimated)
Study Completion 2033-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12